Status:
COMPLETED
Study of VIR-2482 in Healthy Volunteers
Lead Sponsor:
Vir Biotechnology, Inc.
Conditions:
Influenza A
Eligibility:
All Genders
18-64 years
Phase:
PHASE1
Brief Summary
This is a phase 1 study in which healthy volunteers will receive VIR-2482 or placebo and will be assessed for safety, pharmacokinetics, and immunogenicity of VIR-2482 in preventing Influenza A illness...
Eligibility Criteria
Inclusion
- Healthy Male or Female age 18 to \< 65 years
- Body mass index (BMI) of 18.0 kg/m\^2 to 32.0kg/m\^2
Exclusion
- Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation
- History of influenza-like illness or confirmed influenza infection within 3 months prior to randomization.
- Fever-like illness within 5 days of randomization.
- History or clinical evidence of conditions considered high risk for developing influenza-related complications.
Key Trial Info
Start Date :
August 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04033406
Start Date
August 26 2019
End Date
November 1 2021
Last Update
June 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site
Brisbane, Queensland, Australia